Cardiovascular / Natriuretic Research Peptides Guide

This guide covers 3 research peptides in the Cardiovascular / Natriuretic category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.

Nesiritide, a recombinant form of human B-type natriuretic peptide (BNP), is a 32-amino-acid peptide characterized by a 17-residue disulfide ring structure (MW ~3464 g/mol). Initially approved by the FDA in August 2001 under the brand name Natrecor for the treatment of acute decompensated heart failure, its clinical application has diminished significantly following the ASCEND-HF trial in 2011. This pivotal study revealed that nesiritide did not confer a mortality benefit nor did it significantly reduce rehospitalization rates compared to placebo, leading to a reevaluation of its therapeutic efficacy in clinical practice. While nesiritide may still be utilized in specific cases for hemodynamic support, its declining use underscores the importance of ongoing research into alternative treatment modalities for heart failure management.

Atrial natriuretic peptide (ANP), a 28-amino-acid hormone (MW ~3080 g/mol), is predominantly secreted by atrial cardiomyocytes in response to atrial stretch due to volume overload. This peptide plays a crucial role in regulating blood volume, sodium balance, and blood pressure. The recombinant form, carperitide (hANP), received approval in Japan in 1995 for the management of acute heart failure, yet it remains unapproved in the United States, European Union, and other Western markets. Research indicates that ANP serves not only as a therapeutic agent but also as a valuable biomarker in cardiovascular research, providing insights into heart function and fluid status. Despite its established role in Japan, the limited global approval highlights the need for further investigation into its potential applications and benefits in broader clinical contexts.

B-type natriuretic peptide (BNP) is a 32-amino-acid cardiac hormone (MW ~3464 g/mol) primarily secreted by ventricular cardiomyocytes in response to myocardial wall stress caused by volume or pressure overload. BNP is recognized as a critical diagnostic biomarker for heart failure, with assays measuring BNP and its inactive fragment NT-proBNP widely utilized in clinical settings. Furthermore, the therapeutic agent nesiritide, a recombinant form of BNP, has been FDA-approved for acute decompensated heart failure. Originally isolated from porcine brain tissue, BNP’s historical nomenclature reflects its discovery, yet its clinical relevance as both a biomarker and a treatment underscores its significance in cardiovascular research. Ongoing studies continue to explore the potential of BNP and its derivatives in enhancing heart failure management and improving patient outcomes.